Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep150 | Endocrine tumours and neoplasia | ECE2017

Small pancreatic neuroendocrine incidentalomas: an observational prospective study

Villabona C , Busquets J , Martin L San , Planas A , Pelaez N , Fabregat J , Teule A , Peiro I

Background: Diagnosis of small pancreatic neuroendocrine incidentalomas (PNETs-I) is increasing during last years and often their management remains unclear.Objective: To describe our experience with patients with PNETs-I in our institution.Methods: Since March 2000, patients with non functioning PNETs-I ≤30 mm were evaluated in our center, prospectively. A descriptive analysis of all patients and a comparative study between ...

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...